TABLE 2.
Lipid mediator | Q1 | Q3 | E/S (pg/ml) | Lipid mediator | Q1 | Q3 | E/S (pg/ml) |
---|---|---|---|---|---|---|---|
AA bioactive metabolome | E/S | DHA bioactive metabolome | |||||
LXA4 | 351 | 115 | ND | RvD1 | 375 | 215 | — |
LXB4 | 351 | 115 | — | RvD2 | 375 | 215 | — |
5,15(S)-diHETE | 335 | 235 | — | RvD3 | 375 | 181 | — |
AT-LXA4 | 351 | 115 | — | RvD4 | 375 | 255 | — |
AT-LXB4 | 351 | 115 | — | RvD5 | 359 | 199 | — |
LTB4 | 335 | 195 | — | RvD6 | 359 | 101 | — |
20-OH-LTB4 | 351 | 195 | — | AT-RvD1 | 375 | 121 | — |
20-COOH-LTB4 | 365 | 195 | — | AT-RvD3 | 375 | 147 | — |
5,12(S)-diHETE | 335 | 195 | — | PD1 | 359 | 153 | — |
PGD2 | 351 | 189 | 11.6 ± 3.2 | 10,17(S)-diHDHA | 359 | 153 | — |
PGE2 | 351 | 189 | 35,945 ± 516.2 | 22-OH-PD1 | 359 | 153 | — |
PGF2-α | 351 | 193 | 63.5 ± 22.5 | Mar1 | 359 | 221 | — |
TXB2 | 369 | 169 | 1.9 ± 1.0 | 7,14(S)-diHDHA | 359 | 221 | — |
4,14(S)-diHDHA | 359 | 101 | — | ||||
Pathway markers/FA precursors | E/S | ||||||
17-HDHA | 343 | 245 | — | EPA bioactive metabolome | E/S | ||
14-HDHA | 343 | 205 | 0.1 ± 0.0 | RvE1 | 349 | 195 | — |
7-HDHA | 343 | 141 | 0.2 ± 0.1 | RvE2 | 331 | 253 | 0.6 ± 0.2 |
4-HDHA | 343 | 101 | 0.6 ± 0.1 | RvE3 | 333 | 201 | 0.6 ± 0.3 |
DHA | 327 | 283 | 253.4 ± 207.4 | ||||
18-HEPE | 317 | 259 | 0.2 ± 0.2 | ||||
15-HEPE | 317 | 219 | 0.2 ± 0.2 | ||||
12-HEPE | 317 | 179 | — | ||||
5-HEPE | 317 | 115 | 0.2 ± 0.1 | ||||
EPA | 301 | 257 | 53.0 ± 22.4 | ||||
15-HETE | 319 | 219 | 5.1 ± 3.3 | ||||
12-HETE | 319 | 179 | 0.7 ± 0.3 | ||||
5-HETE | 319 | 115 | 1.1 ± 0.3 | ||||
AA | 303 | 259 | 397.6 ± 201.8 |
T. suis worms were cultured for 24 h. The medium containing E/S products was harvested, and LM levels were defined by metabololipidomics. Data are categorized based on their synthesis routes in mammals. Q1, M-H (parent ion); Q3, diagnostic ion in MS-MS (daughter ion). Data are expressed as means ± sem (n = 3). ND, not detected with a limit of detection approximately 0.1 pg.